Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint - Concepedia

Concepedia

Publication | Open Access

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

DOI Full Paper Access

57

Citations

29

References

2018

Year

Ethan Basch, Mark C. Scholz, Johann S. de Bono, Nicholas J. Vogelzang, Paul de Souza, Gavin Marx, Ulka N. Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis,

European Urology

Abstract

Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases.

References

	Year	Citations

Page 1